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AbstrAct
Purpose The research objectives of the Right to Care 
Clinical HIV Cohort analyses are to: (1) monitor treatment 
outcomes (including death, loss to follow-up, viral 
suppression and CD4 count gain among others) for 
patients on antiretroviral therapy (ART); (2) evaluate the 
impact of changes in the national treatment guidelines 
around when to initiate ART on HIV treatment outcomes; 
(3) evaluate the impact of changes in the national 
treatment guidelines around what ART regimens to 
initiate on drug switches; (4) evaluate the cost and 
cost-effectiveness of HIV treatment delivery models; (5) 
evaluate the need for and outcomes on second-line and 
third-line ART; (6) evaluate the impact of comorbidity with 
non-communicable diseases on HIV treatment outcomes 
and (7) evaluate the impact of the switch to initiating all 
patients onto ART regardless of CD4 count.
Participants The Right to Care Clinical HIV Cohort is an 
open cohort of data from 10 clinics in two provinces within 
South Africa. All clinics include data from 2004 onwards. 
The cohort currently has data on over 115 000 patients 
initiated on HIV treatment and patients are followed up 
every 3–6 months for clinical and laboratory monitoring.
Findings to date Cohort data includes information on 
demographics, clinical visit, laboratory data, medication 
history and clinical diagnoses. The data have been used to 
identify rates and predictors of first-line failure, to identify 
predictors of mortality for patients on second-line (eg, 
low CD4 counts) and to show that adolescents and young 
adults are at increased risk of unsuppressed viral loads 
compared with adults.
Future plans Future analyses will inform national models 
of HIV care and treatment to improve HIV care policy in 
South Africa.
IntroductIon
As we enter the second decade of large-scale 
access to antiretroviral therapy (ART) in 
sub-Saharan Africa, there is little question 
about the role that clinical cohorts have 
played in both evaluating and shaping HIV 
policy within the continent.1–3 South Africa, 
with the largest HIV treatment programme in 
the world and over 3 million people on ART, 
has been a leader in this area. The numerous 
clinical cohorts that were established since 
20044–7 have been used to evaluate the changes 
in national treatment policy. One of these 
cohorts, the Themba Lethu Clinical Cohort8 
was established at the Helen Joseph Hospital 
in Johannesburg and has led to numerous 
insights into the effectiveness of the treatment 
roll-out and also participates in larger coun-
try-wide and region-wide evaluations through 
the International Epidemiologic Database to 
Evaluate AIDS (IeDEA) network.7 9 However, 
the Themba Lethu cohort is based at a large 
urban tertiary hospital and as the respon-
sibility for HIV care and treatment shifts 
from hospital based programs to primary 
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Cohort profile
strengths and limitations of this study
 ► The biggest strength of the Right to Care Clinical 
cohort is its size. With over 115 000 patients ever 
initiated onto HIV treatment, precise evaluations can 
be conducted. This is particularly important when 
describing outcomes among subsets of the cohort 
that could not be conducted with much precision 
using individual clinic data.
 ► Second, while the clinics use a similar treatment 
protocol and data collection  strategies, they 
show geographic variation. While other cohort 
collaborations do have such geographic variation, 
few were designed to encompass clinics which 
shared a common software and approach to data 
collection. Further because we link the data to 
the National Health Laboratory Service and the 
National Population Registry, we have high-quality, 
nearly complete data on mortality (for citizens who 
provide an ID), viral load and CD4 counts as well as 
laboratory tests for antiretroviral monitoring such as 
haemoglobin and creatinine.
 ► The main weakness of the data is the lack of 
standardised follow-ups. Because the cohort follows 
changing national guidelines and because specific 
research-based efforts to get patients to adhere 
to treatment visit schedules are not performed, 
we do not always have standard monitoring points 
for all patients within the cohort. This can make 
interpretation of results difficult and requires careful 
consideration of the meaning of missing data.
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Table 1 Routinely collected data for patients in the Right to Care Clinical HIV Cohort, South Africa
Data fields
Demographics Clinic ID, name, national ID number, contact details, gender, date of birth, employment status, alcohol 
use, smoking history, ethnicity, education level
Clinical visit data Date of visit (scheduled and actual), TB screening, urine analysis, vital signs, height, weight, 
description and duration of new symptoms, systems based clinical examination (eg, cardiology, 
neurology, respiratory, etc)
Laboratory results ART initiation and monitoring bloods including CD4 count, HIV viral load, full blood counts, liver 
function tests, renal function tests, TB microscopy and culture results, pap smear screening results, 
lactate levels, glucose and lipid profiles
Medication history Date of start and stop of ART and non-ART medications, reasons for treatment discontinuation, self-
reported treatment adherence
Clinical diagnoses Pregnancy, opportunistic infections including TB, hepatitis, PCP,
AIDS-related malignancies including Kaposi sarcoma and cervical cancer, ART toxicities including 
peripheral neuropathy, anaemia, hyperlactataemia/lactic acidosis, lipoatrophy
ART, antiretroviral therapy; TB, tuberculosis; PCP pneumocystis pneumonia.
healthcare clinics, it has become clear that the Themba 
Lethu Clinical cohort is not sufficient for describing 
the HIV treatment programme in South Africa in its 
entirety. As such, the Right to Care Clinical Cohort, which 
includes the Themba Lethu cohort, has been established 
to provide a broader, more representative perspective on 
South Africa’s HIV care and treatment programme.
cohort descrIPtIon
The Right to Care Clinical Cohort is a network of 10 clinical 
cohorts all established or expanded around 2004 as part 
of the public-sector roll-out of ART in South Africa under 
support from the US Agency for International Develop-
ment from the President’s Emergency Plan for AIDS Relief 
programme. The clinics have all been supported by Right 
to Care, a South African NGO which partners with clin-
ic-based HIV care and treatment programs throughout 
South Africa. As part of their support to clinics, Right to 
Care has provided both data entry and an electronic data 
capturing and patient management system called Ther-
apy-Edge-HIV (TM). Thus, each clinic within the network 
follows a common data entry protocol and uses a stan-
dard database for data capture. Table 1 shows the major 
data fields captured within the database. To oversee the 
data and conduct analyses, Right to Care partners with 
both the individual clinics and the Health Economics and 
Epidemiology Research Office in South Africa, part of 
the Wits Health Consortium which functions as a collab-
oration between the University of the Witwatersrand and 
Boston University. Analysis of anonymised data has been 
approved by the University of the Witwatersrand Human 
Research Ethics Committee and the Boston University 
Institutional Review Board.
Among the individual clinics within the Right to Care 
Clinical Cohort, two are stand-alone HIV clinics while the 
remaining eight are primary healthcare clinics, which 
have an HIV treatment programme. While the individual 
clinics provide fertile ground for evaluating the effects 
of specific drug regimens,10–14 treatment outcomes,15–21 
opportunistic infections22–24 and adverse drug events,10 25 
because the cohort is large and the clinics are diverse 
in location and staff mix but provide care according 
to a standard protocol,26–29 they also create an excel-
lent environment for evaluating large policy changes 
like the recent move to treatment for all, South Africa’s 
national adherence strategy and South Africa’s national 
decanting strategy. In addition, such large collaborations 
are needed both to triangulate the results of other large 
collaborations such as IeDEA30 and to create cohorts 
large enough to evaluate future needs. These include the 
coming wave of patients failing first-line31 and second-line 
treatment12 32–34 and needing access to expensive third-
line regimens or the needs of key populations such as 
pregnant women35 and adolescents in HIV care.17
The Right to Care Clinical Cohort is an open cohort 
and includes all patients enrolled at one of the partici-
pating clinics since April 2004. The clinics included in 
the cohort are located in Gauteng and Mpumalanga prov-
inces within South Africa as shown in figure 1. Of these, 
nine are urban sites while one is in a rural site. All the 
clinics follow the most recent version of the South African 
National HIV Treatment Guidelines,28 though the clinics 
vary in their staffing models.
As of June 2016, across the 10 clinics, 155 144 patients 
have been enrolled, of which 116 490 have initiated ART. 
Currently, 46 241 are actively on ART. The clinics range 
in size from 4332 to 39 297 current patients. Table 2 
summarises the demographic and clinical characteristics 
of the cohort stratified by last treatment regimen. About 
two-thirds of the cohort (63%) are female; most are black 
or of African ethnicity (95%) and the patients have a 
median age of 35 years (IQR 29–42 years). Average CD4 
counts at ART initiation have been increasing over time as 
the treatment thresholds have increased from ≤200 cells/
mm3 in 2004 to ≤350 cells/mm3 in 2011 to ≤500 cells/
mm3 in 2015 to treatment for all in 2016. During that 
group.bmj.com on October 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Fox MP, et al. BMJ Open 2017;7:e015620. doi:10.1136/bmjopen-2016-015620
Open Access
Figure 1 Location of clinics in Right to Care Clinical Cohort.
time, the median (IQR) CD4 count at ART initiation has 
increased from 118 (49–188 cells/mm3) to 241 (97–394 
cells/mm3). South Africa has recently removed CD4 
eligibility thresholds in line with recent WHO recommen-
dations.
Since the large-scale roll-out of ART in South Africa 
in 2004, the recommended drug regimens for both 
first-line and second-line ART have evolved (first-line 
regimens shown in figure 2). Within the cohort, 39 244 
patients are currently on first-line ART. Since 2004, three-
drug first-line therapy has been non-nucleoside reverse 
transcriptase inhibitor (NNRTI) based, with efavirenz 
preferred, but nevirapine is also available. In addition 
to lamivudine, stavudine was the favoured nucleoside 
reverse transcriptase inhibitor in the early years but in 
2010 tenofovir was recommended.
South Africa monitors the effectiveness of HIV 
treatment using viral loads. For patients who have docu-
mented first-line failure (defined as two consecutive viral 
loads≥1000 copies/mL3 at least 2 weeks apart), switching 
to second-line protease inhibitor-based therapy (typi-
cally lopinavir-ritonavir) is recommended. A total of 
5909 patients are currently on second-line ART, making 
it one of the largest second-line cohorts in Africa. More 
recently, access to third-line ART has become available for 
patients failing second-line. Access is managed by appli-
cation to a national third-line committee that will order 
resistance testing and prescribe an appropriate third-
line regimen based on the results. Third-line consists of 
any of darunavir, raltegravir and etravirine. Currently, 
129 patients have been initiated on third-line within the 
cohort.
Follow-up measures
Protocols for follow-up of patients on ART within the 
clinics follow national HIV treatment guidelines that 
have changed over the years. While initially patients were 
required to be seen each month to collect antiretrovi-
rals (ARVs), as the programme has matured, patients 
who have been demonstrated to be adherent and stable 
on treatment can be prescribed 2 or 3 months of ART 
at a time, allowing for fewer visits, a reduced burden 
on the patient and lower clinic volume on a daily basis. 
A total of 116 490 patients who had ART within the 
cohort have contributed a total of 3 42 931 person-years 
on ART. The median (IQR) duration of follow-up per 
person has been 2.17 (0.81–4.41) person-years with 
a range of 0.04 to 12.5 person-years. This equates to 
1 597 690 total medical and 2 262 626 pharmacy visits at 
a rate of 6.6 per year.
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Table 2 Characteristics of patients in the Right to Care Clinical HIV Cohort in South Africa by last treatment regimen
Demographic characteristics First line (N=1 10 452) Second line (N=5909) Third line (N=129)
Gender Female, n (%) 70 590 (63.9) 3822 (64.7) 65 (50.4)
Male, n (%) 39 860 (36.1) 2087 (35.3) 64 (49.6)
Missing, n (%) 2 (0) 0 (0) 0 (0)
Nationality South African, n (%) 96 977 (88.0) 5354 (90.6) 109 (84.5)
Non-South African, n 
(%)
13 176 (12.0) 555 (9.4) 20 (15.5)
Missing, n (%) 299 (0) 2 (0) 0 (0)
Education level No education, n (%) 7372 (6.7) 384 (6.5) 1 (0.8)
Primary, n (%) 18 520 (16.8) 886 (15.0) 33 (25.6)
Secondary, n (%) 56 156 (50.8) 3058 (51.8) 66 (51.2)
Tertiary, n (%) 2179 (2.0) 124 (2.1) 1 (0.8)
Missing, n (%) 26 225 (23.7) 1457 (24.7) 28 (21.7)
Employment status Unemployed, n (%) 58 862 (53.3) 3378 (57.2) 48 (37.2)
Employed, n (%) 43 261 (39.2) 2274 (38.5) 74 (57.4)
Missing, n (%) 8329 (7.5) 257 (4.3) 7 (5.4)
Characteristics at ART initiation
Age (years) Median (IQR) 35.6 (29.4–42.3) 33.9 (28.4–40.1) 36.1 (29.8–41.2)
Body mass index (kg/
m2)
<18.5, n (%) 12 640 (11.4) 754 (12.8) 14 (10.9)
18.5–24.9, n (%) 36 258 (32.8) 1948 (33.0) 35 (27.1)
25–29.9, n (%) 13 289 (12.0) 650 (11.0) 9 (7.0)
30, n (%) 7394 (6.7) 340 (5.8) 11 (8.5)
Missing 40 871 (37.0) 2217 (37.5) 60 (46.5)
Median (IQR) 22.2 (19.4–25.8) 22.0 (19.1–25.3) 22.2 (18.9–26.2)
CD4 count category 
(cells/mm3)
<50, n (%) 18 651 (16.9) 1344 (22.7) 20 (15.5)
50–100, n (%) 13 915 (12.6) 858 (14.5) 16 (12.4)
100–200, n (%) 26 426 (23.9) 1227 (20.8) 17 (13.2)
200–350, n (%) 17 046 (15.4) 578 (9.8) 15 (11.6)
>350, n (%) 7573 (6.9) 262 (4.4) 10 (7.8)
Missing, n (%) 26 841 (24.3) 1640 (27.8) 51 (39.5)
Median (IQR) 137 (58–222) 97 (36–180) 113 (43–257)
HIV viral load (copies/
mL3)
≤1 00 000, n (%) 17 710 (16.0) 1100 (18.6) 28 (21.7)
>1 00 000, n (%) 10 087 (9.1) 786 (13.3) 12 (9.3)
Missing*, n (%) 82 655 (74.8) 4023 (68.1) 89 (69.0)
Haemoglobin level (g/
dL)
Median (IQR) 11.5 (10.0–13.0) 11.4 (10.0–12.8) 11.9 (10.7–13.2)
Tuberculosis Yes, n (%) 9871 (8.9) 632 (10.7) 9 (6.9)
No, n (%) 1 00 381 (91.1) 5258 (89.3) 120 (93.1)
Current status Alive and in care, n (%) 42 542 (38.5) 3605 (61.0) 94 (72.9)
Deceased, n (%) 10 561 (9.6) 261 (4.4) 2 (1.6)
Lost to follow-up, n (%) 28 561 (25.9) 1010 (17.1) 25 (19.4)
Transferred out, n (%) 28 788 (26.1) 1033 (17.5) 8 (6.2)
*HIV viral load was only completed at baseline in the early years of the programme.
Laboratory investigations for all the clinics in the cohort 
are conducted by the National Health Laboratory Service 
(NHLS). While NHLS sends back individual reports to 
the clinics with the results of each investigation, within 
the cohort, data from the NHLS are downloaded directly 
and are integrated into the individual patient database on 
a daily basis, allowing complete and accurate data on lab 
investigations.
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Figure 2 Distribution of first-line antiretroviral therapy 
regimen component drugs by calendar year. 3TC, lamivudine; 
AZT, zidovudine; d4T, stavudine; EFV, efavirenz; FTC, 
emtricitabine; NRTI, nucleoside reverse transcriptase 
inhibitor; NVP, nevirapine; TDF, tenofovir.
Figure 3 Numbers on antiretroviral therapy and viral load suppression over time in the Right to Care HIV Cohort. This analysis 
was cross-sectional, and missing viral loads are not included.
Since the beginning of the programme, CD4 counts 
have been used to determine ART eligibility, with the first 
viral load monitoring being conducted at between 4 and 
6 months on treatment. The interval for monitoring has 
changed from every 6 months after the initial viral load, to 
a 6-month and 12-month viral load and then a repeat viral 
load every year as of 2013. Cohort patients had a median 
(IQR) of 2.1 (0.48–4.6) viral loads per year and a median 
(IQR) of 3 (2–7) viral loads per person. Figure 3 shows 
the increase in numbers on ART and the proportion of 
patients virally suppressed with changes in the national 
guidelines.
Because of the richness and size of the cohort, the data 
have been used to conduct important evaluations of the 
impact of second-line treatment,13 36 of transfer between 
clinics,15 of the impact of changes in CD4 thresholds on 
clinic crowding,37 as well as of the impacts of the shift to 
tenofovir in replacement of stavudine11 38 in the national 
programme. In addition, when warranted, analyses of 
subsets of the data are used to conduct urgent evalua-
tions such as the impact of pregnancy on retention,35 
outcomes within patients on second-line ART33 and 
outcomes for adolescents on ART.39 The data have also 
been successfully used by doctoral students for disserta-
tion work.37
data collection
As noted, all clinics within the cohort have employed a 
common patient data collection system since 2004, the 
TherapyEdge-HIV (TM) patient management system. The 
system is a longitudinal database designed to capture 
essential information from all HIV-related clinic visits.40 
Data are captured on patients both prior to ART initiation 
and after. While the CD4 threshold for ART initiation has 
changed over time, the protocol for patients prior to initi-
ation has been 6-monthly monitoring of CD4 count until 
eligibility is established.
For each patient interaction at a cohort clinic, the 
date of the encounter is recorded allowing for longitu-
dinal follow-up. At the first visit, demographics data are 
collected including key identifiers and information on 
age, sex, race, education, alcohol use and smoking. When 
possible national identifiers are collected to allow linkage 
with national registries and phone numbers are collected 
to allow for patient tracing should patients become lost to 
follow-up. At each follow-up visit, data on clinical condi-
tions that are identified (such as side effects, TB  and 
so on) are captured. At each visit, information is also 
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recorded on any medication dispensed including ARVs 
and other medications.
Overall retention in HIV care in sub-Saharan Africa is 
less than ideal.41–43 Because one of the main uses of these 
data has been to describe the cascade of HIV care,44 45 
no attempts are made to influence retention for research 
purposes. Instead, all measures are taken to reduce attri-
tion as part of usual clinical care. All the clinics within the 
cohort attempt to trace patients who are lost to follow-up, 
though with differing intensities. Each clinic uses its own 
definition of loss for triggering tracing activities, though 
a common definition of 3 months late for an appoint-
ment is used for research purposes and standardising 
loss rates across clinics. At all clinics, tracing is initially 
done through calling the phone number collected at 
enrolment. Some of the clinics also employ tracers or use 
community outreach workers to attempt to trace patients 
who do not return to care.
Mortality is ascertained in multiple ways within the 
cohort. All sites use passive follow-up to identify patients 
who have died and record the information when it is 
reported back by a family member or friend. In addi-
tion, data on all patients who have provided a national 
identification number and who are lost to follow-up are 
cross-referenced with South Africa’s National Popula-
tion Register15 (NPR) to determine final outcomes. The 
proportion of patients who are either in possession of, 
or report their national ID number varies from clinic 
to clinic, ranging from 35% to 74%. Prior to the initial 
linkage between Themba Lethu Clinic and the NPR, 
17% of patients within the clinic were considered lost to 
follow-up and 4% were known to have died. After linkage, 
the proportion who were considered to be lost dropped 
to 10% and the proportion who were recorded to have 
died increased to 11%.15
Another way patients leave the cohort is through 
transfer to another treatment facility. When the patient 
formally requests this it is noted in the database as a 
patient outcome. The rate of transfer within the cohort 
is 12% and varies from 11% to 50%, though those 
at the higher end see this as intentional transfers of 
patients who are ‘down-referred’ to smaller clinics once 
stable.46 47 However, as is common within HIV treatment 
programmes within the region, transfers are often ‘silent 
transfers’ where patients transfer without informing their 
current clinic. Patients who transfer to a new clinic outside 
our network without informing us will appear as lost to 
follow-up. We have shown that this can bias estimates of 
retention in care,48 and therefore the clinics within the 
cohort request patients notify the clinic if they wish to 
receive care elsewhere so that care can be coordinated.
FIndIngs to dAte
The Right to Care Clinical Cohort is used to monitor 
the continued roll-out of ART in South Africa and to 
evaluate the impact of changes in the national treat-
ment programme as they are made. Current areas of 
research include: (1) monitoring treatment outcomes 
(including death, loss to follow-up, viral suppression, 
CD4 count gain, etc) for patients on ART; (2) evaluating 
the impact of changes in the national treatment guide-
lines around when to initiate ART on HIV treatment 
outcomes; (3) evaluating the impact of changes in the 
national treatment guidelines around what ART regi-
mens to initiate on drug switches; (4) evaluating the cost 
and cost-effectiveness of HIV treatment delivery models; 
(5) evaluating the need for and outcomes on second-
line and third-line ART; (6) evaluating the impact of 
comorbidity with non-communicable diseases on HIV 
treatment outcomes and (7) evaluating the impact of 
the switch to initiating all patients onto ART regardless 
of CD4 count.
To date, we have used the Right to Care cohort to 
evaluate various aspects of the national HIV treatment 
programme. Three examples of this work include:
 ► Treatment outcomes. While numerous models have 
found important predictors of failing first-line thera-
py, few have had the size to be able to develop a pre-
cise predictive model of treatment failure.49 Using 
data on 71 154 individuals, we showed that age, sex, 
interactions between age and sex, first-line NNRTI, 
CD4 count, mean corpuscular volume, haemoglo-
bin level, history of TB and missed visits during the 
first 6 months on ART were predictive of failure. After 
stratifying into risk groups, failure in the highest risk 
group was 24.4% over 5 years on ART but only 9.4% 
among the lowest risk group, allowing stratification of 
risk for clinics.49
 ► Second-line ART outcomes. The need for second-line 
treatment has been growing as treatment scale up has 
continued, but there is little robust data on outcomes 
among patients who have already failed a first-line 
regimen.34 With data on 1435 patients on second-line 
ART between 2004 and 2013, we found that a low 
CD4 count (<50 cells/mm3) at the time of switch was 
strongly predictive of mortality (adjusted HR (aHR) 
vs  ≥200 cells/mm3: 3.76; 95% CI: 1.87 to 7.57) as was 
a high viral load (≥50 000 copies/mL vs 1000–4999 
copies/mL aHR: 2.01; 95% CI: 1.07 to 3.77).33 The 
results suggest that earlier switch would likely benefit 
patients failing first-line before disease progresses to 
severe immunosuppression.
 ► Outcomes for adolescents on HIV treatment. While having 
been identified as a key population for ending the 
AIDS epidemic, few cohorts have been able to meas-
ure outcomes among adolescents on HIV treatment 
in resource-limited settings because there are not suf-
ficient numbers. Comparing 310 adolescents 10–14 
years, 342 adolescents 15–19 and 1599 young adults 
20–24 years to adults ≥25 years, we found both older 
adolescents (adjusted risk ratio (RR) 1.75 95% CI 1.25 
to 2.47) and young adults (RR 1.33 95% CI 1.10 to 
1.60) were at increased risk of an unsuppressed viral 
load compared with adults17 suggesting they need to 
be targeted for additional intervention.
group.bmj.com on October 26, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 7Fox MP, et al. BMJ Open 2017;7:e015620. doi:10.1136/bmjopen-2016-015620
Open Access
Perhaps the biggest strength of the Right to Care Clin-
ical cohort is its size. With over 1 15 000 patients ever 
initiated onto HIV treatment, precise evaluations can be 
conducted. This is particularly important when describing 
outcomes among subsets of the cohort that could not be 
conducted with much precision using individual clinic 
data. For example, by pooling data across 10 clinics, we 
are able to conduct precise analyses on a large cohort of 
patients initiating second-line therapy.
Second, while the clinics use a similar treatment protocol 
and data collections strategies, they show geographic vari-
ation. While other cohort collaborations do have such 
geographic variation, few were designed to encompass 
clinics which shared a common software and approach 
to data collection. Further because we link the data to 
the NHLS and the National Population Registration, we 
have high-quality, nearly complete data on mortality (for 
citizens who provide an ID), viral load and CD4 counts 
as well as ARV monitoring labs such as haemoglobin and 
creatinine.
Perhaps the main weakness of the data is the lack of stan-
dardised follow-ups. Because the cohort follows changing 
national guidelines and because specific research-based 
efforts to get patients to adhere to treatment visit sched-
ules are not performed, we do not always have standard 
monitoring points for all patients within the cohort. This 
can make interpretation of results difficult and requires 
careful consideration of the meaning of missing data. It 
also calls for the use of missing data methods50 and formal 
quantitative bias analysis51–54 to explore the impact of any 
systematic errors. In addition, because the cohort is not 
designed as a research cohort, biological samples are not 
collected at routine intervals (beyond what is required for 
clinical care) and these samples are not stored. There-
fore, we cannot use the cohort to study topics such as 
molecular epidemiology or biomarker research. Because 
the cohort is meant to reflect what is happening in actual 
clinic care, such samples will continue to not be stored 
going forward.
collAborAtIons
Investigators wishing to work with the data should contact 
the team at the Health Economics and Epidemiology 
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